| Dr Howard M Glicksman, MD | |
|
7154 Medical Center Drive, Spring Hill, FL 34608-1329 | |
| (352) 596-1926 | |
| (352) 597-2154 |
| Full Name | Dr Howard M Glicksman |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 7154 Medical Center Drive, Spring Hill, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568424836 | NPI | - | NPPES |
| P00468392 | Other | FL | RAILROAD MEDICARE |
| 068222500 | Medicaid | FL |
| Entity Name | Connexis Medical Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699002097 PECOS PAC ID: 2163550518 Enrollment ID: O20100506000158 |
News Archive
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Regulus Therapeutics Inc. announced today that the Company has received a $10 million equity investment from sanofi-aventis in connection with the landmark alliance the two companies entered into on June 21, 2010. The equity investment by sanofi-aventis further strengthens the balance sheet of Regulus, and with this investment sanofi-aventis becomes the third investor in Regulus, along with its founding companies Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc..
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Quidel Corporation, a leading provider of rapid diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of Quidel's RapidVue® hCG test, a lateral flow pregnancy immunoassay for the qualitative detection of human Chorionic Gonadotropin (hCG).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Howard M Glicksman, MD 17757 Us Hwy 19 North, Suite 400, Clearwater, FL 33764-6560 Ph: (727) 450-2210 | Dr Howard M Glicksman, MD 7154 Medical Center Drive, Spring Hill, FL 34608-1329 Ph: (352) 596-1926 |
News Archive
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Regulus Therapeutics Inc. announced today that the Company has received a $10 million equity investment from sanofi-aventis in connection with the landmark alliance the two companies entered into on June 21, 2010. The equity investment by sanofi-aventis further strengthens the balance sheet of Regulus, and with this investment sanofi-aventis becomes the third investor in Regulus, along with its founding companies Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc..
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
Quidel Corporation, a leading provider of rapid diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of Quidel's RapidVue® hCG test, a lateral flow pregnancy immunoassay for the qualitative detection of human Chorionic Gonadotropin (hCG).
› Verified 1 days ago
Ms. Maria R Guzman Tennant, M.D. General Practice Medicare: Medicare Enrolled Practice Location: 5350 Spring Hill Dr, Spring Hill, FL 34606 Phone: 352-688-8116 Fax: 352-686-9477 | |
Dr. Evelyn E Castillo Delgado, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 3021 Commercial Way, Spring Hill, FL 34606 Phone: 352-688-8116 Fax: 352-686-9477 | |
Michael Rudelli, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 5350 Spring Hill Dr, Spring Hill, FL 34606 Phone: 352-277-5378 Fax: 352-515-6891 | |
Dr. Jorge L Gaud Morales, M.D. General Practice Medicare: Medicare Enrolled Practice Location: 5350 Spring Hill Dr, Spring Hill, FL 34606 Phone: 352-688-8116 Fax: 352-686-9477 | |
Charlene Edmee D'acosta, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 5350 Spring Hill Dr, Spring Hill, FL 34606 Phone: 352-688-8116 Fax: 352-686-9477 | |
Dr. Keivan A Tavakoli, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 5350 Spring Hill Dr, Spring Hill, FL 34606 Phone: 352-688-8116 Fax: 352-686-9477 | |
Mari Trini Castello, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 3588 Swordfish Ln, Spring Hill, FL 34609 Phone: 787-485-5492 |